观点聚焦 Investment Focus
disclaimer)
爱美客 Imeik Technology Development (300896 CH)
业绩增速超股权激励目标，核心产品持续放量
Performance Growth Exceeded the Employee Stock Ownership Plan Core Products Continue Grow
维持优于大市Maintain OUTPERFORM
Rmb7405bn  US1029bn
日交易额 (3 个月均值)
US15506mn
1 年股价最高最低值
注：现价Rmb34224 为2024 年3 月20 日收盘价
资料来源： Factset
资料来源：公司信息 HTI
(Please see APPENDIX 1 for English summary)
事件：公司发布2023 年年报
公司2023 年实现收入287 亿元（4799%），归母净利润186 亿
元（4708%），扣非归母净利润183 亿元（5295%）。毛利率
和净利率分别为951%（03pct），648%（-04pct）。三项费用
率稳定，销售、管理、研发费用率分别为91%（07pct），50%
（-16pct），87%（-02pct）。单Q4 收入70 亿元（5555%），
归母净利润44 亿元（5900%）。
分产品来看：以嗨体为代表的溶液类注射产品收入167 亿元
（2922%），实现销量51413 万支（4888%）。凝胶类注射产
亿元（8143% ），销量实现10068
（3613%），得益于天使针系列的放量， 2023 年凝胶类注射产
品的ASP 约为1150 元，提升幅度为33%，建议持续关注天使针
直销为主和经销为辅的营销模式助力爱美客在终端的差异化发
展。销售和市场团队超400 人，覆盖全国约7000 家医疗终端，
2023 年直销和经销收入占比分别为623%和377%。我们认为直销
可以深度触及客户，终端意见有助于开发效率提升。经销模式有
助于扩大产品市占率。
重点布局研发，在研管线丰富。目前处于注册申报阶段项目2 个
（医用含聚乙烯醇凝胶微球的修饰透明质酸钠凝胶增加颏部填充
适应症，注射用A 型肉毒素）；临床试验阶段项目4 个；临床前项
目3 个。2023 年公司持续对外合作，丰富产品管线，包括引进司
美格鲁肽；与韩国Jeisys 合作，负责旗下两款美容治疗设备及耗材
在中国大陆的推广、销售及服务。
盈利预测和估值 ：我们预计2024-2026 年的收入分别为3954 亿
5331 亿6488 亿元，同比增长378%348%217%（前值2024-
2025 年为4171 亿元和5690 亿元，调整原因系宏观环境变化对产
品放量速度的影响），归母净利润分别为2455 亿3191 亿3829
亿元，同比增速为321%300%200%，（前值2024-2025 年为
2624 亿元3509 亿元，同上）。根据可比公司，我们认为爱美客
作为行业龙头，有品牌和渠道壁垒，维持目标价6693 元，对应
24-26 年PE分别为40x27x22x，维持优于大市评级，建议关注。
医美行业政策影响，宏观环境对医美赛道景气度的影响，研发及
销售不及预期等风险。
爱美客 (300896 CH)
资料来源：Wind（20240320）；海通国际；注：欧普康视2023 年PE 为Wind 预测值。
爱美客 (300896 CH)
资产负债表（百万元）
现金流量表（百万元）
备注：（1）表中计算估值指标的收盘价日期为2024 年3 月20 日；（2）以上各表均为简表
资料来源：公司年报，HTI
爱美客 (300896 CH)
APPENDIX 1
( 4708%) net profit attribute to the shareholders after deducting non-recurring gains and losses of CNY183 billion ( 5295%)
GPM and NPM were 951% ( 03pct) 648% (04pct) Expense rates are stable with sales management and RD rates of 91%
( 07pct) 50% (-16pct) and 87% (-02pct) respectively The Q4 revenue was CNY070 billion ( 5555%) net profit attribute to
shareholders of CNY044 billion ( 5900%)
Sub-products Revenue of solution injection products represented by Hearty was CNY167 billion ( 2922%) sold 51413 million
units ( 4888%) Revenue of gel injection products was CNY116 billion ( 8143%) sold 10068 million units ( 3613%) benefited
continue to pay attention to the performance of angel needle series products 
With a sales and marketing team of more than 400 people covering about 7000 medical terminals across the country the share
of direct sales and distribution revenue in 2023 was 623% and 377% respectively We believe that direct sales can reach customers
in depth and that end opinions can help to improve development efficiency The distribution model helps to expand pro duct
market share
phase including medical polyvinyl alcohol gel microspheres of modified sodium hyaluronate gel to increase chin filling indications
cooperate abroad to enrich the product pipeline including the introduction of Smegelutide In collaboration with Jeisys Korea
mainland China
Revenue forecast and valuation We expect revenue in 2024-2026 to be CNY3954 billion5331 billion6488 billion respectively
up 378%348%217% year-on-year (Pre-value was CNY4171 billion and CNY569 billion in 2024-2025 The reason for the
adjustments is the effect of macro-environmental change on the sale of products) The net profit attribute to shareholders are
estimated to be CNY2455 billion3191 billion3829 billion respectively with a year-on-year growth rate of 321 %300 %200%
40x27x22x and the OUTPERFORM rating
Aesthetic medicine industry policy impact the macro environment on aesthetic medicine economic impact RD and sales below
expectations and other risks
APPENDIX 2
Environmental
Governance
IMPORTA NT DISCLOS URES
This research report is distributed by Haitong International a global brand name for the equity research teams of Haitong International Research Limited (HTIRL) Haitong Securities India Privat e
Limited (HSIPL) Haitong International Japan KK (HTIJKK) Haitong International Securities Company Limited (HTISCL) and any other members within the Haitong International Securities Group
of Companies (HTISG) each authorized to engage in securities activities in its respective jurisdiction
我， 孟科含，在此保证（i）本研究报告中的意见准确反映了我们对本研究中提及的任何或所有目标公司或上市公司的个人观点，并且（ii）我的报酬中没有任何部分与本研究报告中表
whom I have already notified of this will not deal in or trade any securities in respect of the issuer that I review within 3 business days after the research report is published
我， 孙旭东，在此保证（i）本研究报告中的意见准确反映了我们对本研究中提及的任何或所有目标公司或上市公司的个人观点，并且（ii）我的报酬中没有任何部分与本研究报告中表
expressed in this research report and that I (including members of my household) have no financial interest in the security
whom I have already notified of this will not deal in or trade any securities in respect of the issuer that I review within 3 business days after the research report is published
利益冲突披露Conflict of Interest Disclosures
海通国际及其某些关联公司可从事投资银行业务和或对本研究中的特定股票或公司进行做市或持有自营头寸。就本研究报告而言，以下是有关该等关系的披露事项（以下披露不能保
评级定义（从2020 年7 月1 日开始执行）：
海通国际（以下简称HTI ）采用相对评级系统来为投资者推荐我们覆盖的公
司：优于大市、中性或弱于大市。投资者应仔细阅读HTI 的评级定义。并且HT I
基于各自情况（比如投资者的现有持仓）以及其他因素。
优于大市，未来12-18 个月内预期相对基准指数涨幅在10%以上，基准定义如
中性，未来12-18 个月内预期相对基准指数变化不大，基准定义如下。根据
FINRANYS E 的评级分布规则，我们会将中性评级划入持有这一类别。
弱于大市，未来12-18 个月内预期相对基准指数跌幅在10%以上，基准定义如
各地股票基准指数：日本  TOPIX 韩国  KOSPI 台湾  TAIEX 印度  Nifty100 美
国  SP500 其他所有中国概念股  MSCI China
Ratings Definitions (from 1 Jul 2020)
Haitong International uses a relative rating system using Outperform 
Neutral or Underperform
investors Investors should carefully read the definitions of all ratings used
in Haitong International Research In addition since Haitong Internationa l
views investors should carefully read Haitong International Research in its
entirety and not infer the contents from the rating alone In any case
ratings (or research) should not be used or relied upon as investment
评级分布Rating Distribution
advice An investors decision to buy or sell a stock should depend on
individual circumstances (such as the investors existing holdings) and other
considerations
Analyst Stock Ratings
Outperform
The stocks total return over the next 12-18 months is
expected to exceed the return of its relevant broad market benchmark as
indicated below
Neutral The stocks total return over the next 12-18 months is expected to
be in line with the return of its relevant broad market benchmark as
indicated below For purposes only of FINRANYSE ratings distributio n
rules our Neutral rating falls into a hold rating category
Underperform The stocks total return over the next 12-18 months is
expected to be below the return of its relevant broad market benchmark
as indicated below
Benchmarks for each stocks listed region are as follows Japan  TOPIX
Korea  KOSPI Taiwan  TAIEX India  Nifty100 US  SP500 for all other
China-concept stocks  MSCI China
截至2023 年12 月31 日海通国际股票研究评级分布
在每个评级类别里投资银行客户所占的百分比。
上述分布中的买入，中性和卖出分别对应我们当前优于大市，中性和落后大市评级。
只有根据FINRANYS E 的评级分布规则，我们才将中性评级划入持有这一类别。请注意在上表中不包含非评级的股票。
此前的评级系统定义（直至2020 年6 月30 日）：
买入，未来12-18 个月内预期相对基准指数涨幅在10%以上，基准定义如下
中性，未来12-18 个月内预期相对基准指数变化不大，基准定义如下。根据F INRANYS E 的评级分布规则，我们会将中性评级划入持有这一类别。
卖出，未来12-18 个月内预期相对基准指数跌幅在10%以上，基准定义如下
各地股票基准指数：日本  TOPIX 韩国  KOSPI 台湾  TAIEX 印度  Nifty100 其他所有中国概念股  MSCI China
Haitong International Equity Research Ratings Distribution as of December 31 2023
HTI Equit y Research Coverag e
IB client s
Percentage of invest ment banking clients in each rating category
BUY Neutral and SELL in the above distribution correspond to our current ratings of Outperform Neutral and Underperform
For purposes only of FINRANYS E ratings distribution rules our Neutral rating falls into a hold rating category Please note that stocks with an NR designation are not included in the table above
Previous rating system definitions (until 30 Jun 2020)
BUY The stocks total return over the next 12-18 months is expected to exceed the return of its relevant broad market benchmark as indicated below
NEUTRAL The stocks total return over the next 12-18 months is expected to be in line with the return of its relevant broad market benchmark as indicated below For purposes
only of FINRANYSE ratings distribution rules our Neutral rating falls into a hold rating category
SELL The stocks total return over the next 12-18 months is expected to be below the return of its relevant broad market benchmark as indicated below
Benchmarks for each stocks listed region are as follows Japan  TOPIX Korea  KOSPI Taiwan  TAIEX India  Nifty100 for all other China-concept stocks  MSCI China
海通国际非评级研究：海通国际发布计量、筛选或短篇报告，并在报告中根据估值和其他指标对股票进行排名，或者基于可能的估值倍数提出建议价格。这种排名或建议价格并非为
了进行股票评级、提出目标价格或进行基本面估值，而仅供参考使用。
Haitong International Non-Rated Research  Haitong International publishes quantitative screening or short reports which may rank stocks according to valuation an d other metrics or may sugg est
prices based on possible valuation multiples Such rankings or suggested prices do not purport to be stock ratings or target prices or fundament al values and are for information only
Haitong International Coverage of A-Shares  Haitong International may cover and rate A-Shares that are subject to the Hong Kong Stock Connect scheme with Shanghai and Shenzhen Hait ong
system employed by HS differs from that used by HTI and as a result there may be a difference in the HTI and HS ratings for the same A-share stocks
股团队自下而上的研究。海通国际每季对Q100 指数成分作出复审。
Haitong International Quality 100 A-share (Q100) Index  HTIs Q100 Index is a quant product that consists of 100 of the highest-qualit y A-shares under coverage at HS in Shanghai These stocks are
盟浪义利（FIN-ESG）数据通免责声明条款：在使用盟浪义利（FIN-ES G）数据之前，请务必仔细阅读本条款并同意本声明：
第一条 义利（FIN-ES G）数据系由盟浪可持续数字科技有限责任公司（以下简称本公司）基于合法取得的公开信息评估而成，本公司对信息的准确性及完整性不作任何保证。对公司
的评估结果仅供参考，并不构成对任何个人或机构投资建议，也不能作为任何个人或机构购买、出售或持有相关金融产品的依据。本公司不对任何个人或机构投资者因使用本数据表
述的评估结果造成的任何直接或间接损失负责。
第二条 盟浪并不因收到此评估数据而将收件人视为客户，收件人使用此数据时应根据自身实际情况作出自我独立判断。本数据所载内容反映的是盟浪在最初发布本数据日期当日的判
断，盟浪有权在不发出通知的情况下更新、修订与发出其他与本数据所载内容不一致或有不同结论的数据。除非另行说明，本数据（如财务业绩数据等）仅代表过往表现，过往的业
绩表现不作为日后回报的预测。
第三条 本数据版权归本公司所有，本公司依法保留各项权利。未经本公司事先书面许可授权，任何个人或机构不得将本数据中的评估结果用于任何营利性目的，不得对本数据进行修
改、复制、编译、汇编、再次编辑、改编、删减、缩写、节选、发行、出租、展览、表演、放映、广播、信息网络传播、摄制、增加图标及说明等，否则因此给盟浪或其他第三方造
成损失的，由用户承担相应的赔偿责任，盟浪不承担责任。
第四条 如本免责声明未约定，而盟浪网站平台载明的其他协议内容（如盟浪网站用户注册协议盟浪网用户服务（含认证）协议盟浪网隐私政策等）有约定的，则按其他
协议的约定执行；若本免责声明与其他协议约定存在冲突或不一致的，则以本免责声明约定为准。
SusallWav e FIN-ES G Data Service Disclaimer  Please read these terms and conditions below carefully and confirm your agreement and accept ance with these terms before using SusallWave FIN -
ESG Data Service
FIN-ESG Data is produced by SusallWave Digital Technolog y Co Ltd (In short SusallWave)s assessment based on legal publicly a ccessible information SusallWave shall not be responsib l e
selling or holding any relative financial product s We will not be liable for any direct or indirect loss of any individual or institution as a result of using SusallWave FIN -ESG Data
SusallWave do not consider recipients as customers for receiving these data When using the data recipients shall make  your own independent judgment according to your practical individual
status The contents of the data reflect the judgment of us only on the release day We have right to update and amend the da ta and release other data that contains inconsistent contents or
different conclusions without notification Unless expressly stated the data (eg financial performance data) represents p ast performance only and the past performance cannot be viewed as the
prediction of future return
The copyrig ht of this data belongs to SusallWave and we reserve all rights in accordance with the law Without the prior written permission of our co mpany none of individual or institut ion
abbreviation excerpts issuance rent exhibition performance projection broadcast information network transmission sho oting  adding icons and instructions If any loss of SusallWave or any
If any term is not contained in this disclaimer but written in other agreement s on our website (eg User Registration Protocol of SusallWave Website User Service (including authenticat io n )
Agreement of SusallWave Website Privacy Policy of Susallwave Website) it should be executed according to other agreement s If there is any difference between this disclaim and other agreeme nt s 
this disclaimer shall be applied
行，包括制作及发布涵盖BSE Limited（BSE）和National Stock Exchange of India Limited（NS E）上市公司（统称为印度交易所）的研究报告。HTSIPL 于2016 年12 月22 日被收购
声明或保证。本文件中所有观点均截至本报告日期，如有更改，恕不另行通知。本文件仅供参考使用。文件中提及的任何公司或其股票的说明并非意图展示完整的内容，本文件并非
可能会对投资产生不利影响。过去的表现并不一定代表将来的结果。某些特定交易，包括设计金融衍生工具的，有产生重大风险的可能性，因此并不适合所有的投资者。您还应认识到
其他方面的专业顾问，以期在投资之前评估该项建议是否适合于您。若由于使用本文件所载的材料而产生任何直接或间接的损失，HTISG 及其董事、雇员或代理人对此均不承担任何责
HTISG 的销售员、交易员和其他专业人士均可向HTIS G 的相关客户和公司提供与本文件所述意见相反的口头或书面市场评论意见或交易策略。HTIS G 可做出与本文件所述建议或意见不
一致的投资决策。但HTIRL 没有义务来确保本文件的收件人了解到该等交易决定、思路或建议。
IMPORTA NT DISCLAIM ER
For research reports on non-Indian securities The research report is issued by Haitong International Research Limited (HTIRL) a wholly owned subsidiary of Haitong International Securities Group
Limited (HTISGL) and a licensed corporation to carry on Type 4 regulated activity (advising on securities) for the purpose of the Securities and F utures Ordinance (Cap 571) of Hong Kong with the
assistance of Haitong International (Japan) KK (HTIJKK) a wholly owned subsidiary of HTISGL and which is regulated as an  Invest ment Adviser by the Kanto Finance Bureau of Japan
registered Stock Broker Merchant Banker and Research Analyst that inter alia produces and distributes research repo rts covering listed entities on the BSE Limited (BSE) and the National St ock
Exchang e of India Limited (NSE) (collectively referred to as Indian Exchang es) HSIPL was acquired and became part of the  Haitong International Securities Group of Companies (HTISG) on 22
December 2016
All the research reports are globally branded under the name Haitong International and approved for distribution by Haitong I nternational Securities Company Limited (HTISCL) andor any other
members within HTISG in their respective jurisdictions
referred to in this research report may not be eligible for purchase or sale in some jurisdictions If an investment product is denominated in a currency other than an investors home currency a
change in exchange rates may adversely affect the investment  Past performance is not necessarily indicative of future results Certain tran sactions including those involving derivatives give rise to
your unique financial circumstances such as your financial situation and risk appetite You must therefore analyze and sho uld where applicable consult your own legal tax accounting  financial
for any direct or consequential loss arising from any use of the materials contained in this research report
HTISG and our affiliates officers directors and employees excluding the analysts responsible for the content of this docu ment will from time to time have long or short positions in act as principal
to the attention of any recipient of this research report
with respect to Research
Non US Analyst Disclosure  The HTI analyst(s) listed on the cover of this Research is (are) not registered or qualified as a  research analyst with FINR A and are not subject to US FINRA Rule 2241
期货事务监察委员会的审查。您不应仅根据本研究报告中所载的信息做出投资决定。本研究报告的收件人就研究报告中产生或与之相关的任何事宜请联系HTIS CL 销售人员。
美国投资者的通知事项：本研究报告由HTIRL，HSIPL 或HTIJKK 编写。 HTIRL，HSIPL，HTIJKK 以及任何非HTIS G 美国联营公司，均未在美国注册，因此不受美国关于研究报告编制和研
资者（US Institutional Investors）。在向美国机构投资者分发研究报告时，Hait ong International Securities (USA) Inc （HTI USA） 将对报告的内容负责。任何收到本研究报告的美国
351-6050。 HTI USA 是在美国于US Securities and Exchang e Commission （SEC）注册的经纪商，也是Financial Industry Regulatory Authorit y Inc（FINRA）的成员。 HTIUSA 不负责编写
Haitong International Securities (USA) Inc
340 Madison Avenue 12th Floor
New York NY 10173
DISTRIBUTION AND REGIONA L NOTICES
Except as otherwise indicated below any Recipient wishing to discuss this research report or effect any transaction in any s ecurity discussed in HTIs research should contact the Haitong Internatio n al
salesperson in their own country or region
Notice to Hong Kong investors The research report is distributed by Haitong International Securities Company Limited (HTISCL) which is a licensed corpor ation to carry on Type 1 regulated activit y
(dealing in securities) in Hong Kong This research report does not constitute a solicitation or an offer of securities or an invitation to the public within the meaning of the SFO This re search report
is only to be circulated to Professional Investors as defined in the SFO This research report has not been reviewe d by the Securities and Futures Commission You should not make invest m e nt
decisions solely on the basis of the information contained in this research report Recipients of this research report are to  contact HTISCL salespersons in respect of any matters arising from or in
connect ion with the research report
Notice to US investors As described above this research report was prepared by HTIRL HSIPL or HTIJKK Neither HTIRL HSIPL HTIJKK nor any of the  non US HTISG affiliates is registered in the
United States and therefore is not subject to US rules regarding the preparation of research reports and the independence  of research analysts  This research report is provided for distribution to
major US institutional investors and US institutional investors in reliance on the exemption from registration provided by Rule 15a -6 of the US Securities Exchange Act of 1934 as amended 
When distributing research reports to US institutional investors HTI USA will accept the responsibilities for the content of the reports  Any US recipient of this research report wishing to effect
any transaction to buy or sell securities or related financial instrument s based on the information provided in this research  report should do so only through Haitong International Securities (US A)
Inc (HTI USA) located at 340 Madison Avenue 12th Floor New York NY 10173 USA telephone (212) 351 6050   HTI USA is a broker-dealer registered in the US with the US Securities and
Exchang e Commission (the SEC) and a member of the Financial Industry Regulatory Authorit y Inc (FINRA)  HTI USA is not responsible for the preparation of this research report nor for the
analysis contained therein  Under no circumstances should any US recipient of this research report contact the analyst directly or effect any transaction to buy or sell securities or related financial
instrument s directly through HSIPL HTIRL or HTIJKK  The HSIPL HTIRL or HTIJKK analyst(s) whose name appears in this research report is not r egistered or qualified as a research analyst with FINRA
in any non-US  securities or related financial instrument s (including ADRs) discussed in this research report may present certain risks   The securities of non-US  issuers may not be registered wit h
financial instrument s All inquiries by US recipients should be directed to
Haitong International Securities (USA) Inc
340 Madison Avenue 12th Floor
New York NY 10173
Attn  Sales Desk at (212) 351 6050
中华人民共和国的通知事项：在中华人民共和国（下称中国，就本报告目的而言，不包括香港特别行政区、澳门特别行政区和台湾）只有根据适用的中国法律法规而收到该材料的人
103 Registration Requirements Exemptions and Ongoing Registrant Obligations （NI 31-103）的规定得到国际交易商豁免（International Dealer Exemption ）的交易商，位于艾伯塔
National Instrument 45-106 Prospect us Exempti ons 第11 节或者S ecurities Act (Ontario)第733(1)节所规定的认可投资者（Accredit ed Investor），或者在适用情况下Nati o n al
Instrument 31-103 第11 节所规定的许可投资者（Permitt ed Investor）。
新加坡投资者的通知事项：本研究报告由Hait ong International Securities (Singapore) Pte Ltd（HTIS SPL）公司注册编号201311400G 于新加坡提供。HTIS S PL 是符合财务顾问法（第
题，本研究报告的收件人应通过以下信息与HTISS PL 联系：
Haitong International Securities (Singapore) Pte Ltd
50 Raffles Place 33-03 Singapore Land Tower Singapore 048623
（1）条，第17-11（1）条的执行及相关条款）。
相关的投资行为只面对此类专业客户。没有投资经验或相关投资经验的客户不得依赖本报告。Hait ong International Securities Company Limited 的分支机构的净长期或短期金融权益可能
超过本研究报告中提及的实体已发行股本总额的05。特别提醒有些英文报告有可能此前已经通过中文或其它语言完成发布。
澳大利亚投资者的通知事项：Haitong International Securities (Singapore) Pte Ltd Haitong International Securities Company Limited 和Hait ong International Securities (UK) Limited 分别根据澳
提供金融服务时海通国际需持有澳大利亚金融服务许可的要求。AS IC 的规章副本可在以下网站获取：ww wlegislationg ovau。海通国际提供的金融服务受外国法律法规规定的管制，该
等法律与在澳大利亚所适用的法律存在差异。
发布，包括制作及发布涵盖BS E Limited（BSE）和Nat ional Stock Exchang e of India Limited （NS E）（统称为印度交易所）研究报告。
研究机构名称 Haitong Securities India Private Limited
841 Senapati Bapat Marg Elphinstone Road Mumbai 400 013 India
请注意，S EBI 授予的注册和 NISM 的认证并不保证中介的表现或为投资者提供任何回报保证。
本项研究仅供收件人使用，未经海通国际的书面同意不得予以复制和再次分发。
Peoples Republic of China (PRC) In the PRC the research report is directed for the sole use of those who receive the research report in accordance with the applicable PRC laws and regulations 
Further the information on the research report does not constitut e production and business activities in the PRC under rel evant PRC laws This research report does not constitute a public offer
of the security whether by sale or subscription in the PRC Further no legal or natural persons of the PRC may directly or indirectly purchase any of the securi ty or any beneficial interest therein
these restrictions
Notice to Canadian Investors Under no circumst ances is this research report to be construed as an offer to sell securities or as a solicitation of an offe r to buy securities in any jurisdiction of Canada
Any offer or sale of the securities described herein in Canada will be made only under an exemption from the requirement s to file a prospect us with the relevant Canadian securities regulators and
only by Haitong International Securities (USA) Inc a dealer relying on the international dealer exemption under National Instrument 31-103 Registration Requirement s Exemptions and Ong oing
Registrant Obligations (NI 31-103) in Alberta British Columbia Ontario and Quebec This research report is not and under no circumst ances should be con strued as a prospect us an offering
research report the information contained herein or the merits of the securities described herein and any representation to the contrary is an offence Upon receipt of this research report each
Canadian recipient will be deemed to have represented that the investor is an accredit ed investor as such term is defined i n section 11 of National Instrument 45-106 Prospect us Exemptions or
in Ontario in section 733(1) of the Securities Act (Ontario) as applicable and a permitted client as such term is defin ed in section 11 of NI 31-103 respectively
Notice to Singapore investors This research report is provided in Singapore by or through Haitong International Securities (Singapore) Pte Ltd (HTISSPL) Co Reg No 201311400G HTISSPL is an
Exempt Financial Adviser under the Financial Advisers Act (Cap 110) (FAA) to (a) advise on securities units in a collective investment scheme exchange -t raded derivatives contracts and over-t h e -
counter derivatives contracts and (b) issue or promulgat e research analyses or research reports on securities exchang e -traded derivatives contracts and over-the-count er derivatives contracts This
research report is only provided to institutional investors within the meaning of Section 4A of the Securities and Futures Act (Cap 289) Recipient s of this research report are to contact HTISSPL via
the details below in respect of any matters arising from or in connection with the research report
Haitong International Securities (Singapore) Pte Ltd
10 Collyer Quay 19-01 - 19-05 Ocean Financial Centre Singapore 049315
Telephone (65) 6536 1920
Notice to Japanese investors This research report is distributed by Haitong International Securities Company Limited and intended to be distributed to Fin ancial Services Providers or Regist ere d
Financial Institutions engaged in investment management (as defined in the Japan Financial Instruments and Exchange Act (FIEL) Art 61(1) Order for Enforcement of FIEL Art 17 -11(1) and relat ed
articles)
Notice to UK and European Union investors This research report is distributed by Haitong International Securities Company Limited This research is directed at persons having professi o n al
experience in matters relating to investment s Any investment or investment activity to which this research relates is availa ble only to such persons or will be engaged in only with such persons
Persons who do not have professional experience in matters relating to invest ment s should not rely on this research   Haitong International Securities Company Limiteds affiliates may have a net
long or short financial interest in excess of 05% of the total issued share capital of the entities mentioned in this research report  Please be aware that any report in English may have been publishe d
previously in Chinese or another language
Notice to Australian investors The research report is distributed in Australia by Haitong International Securities (Singapore) Pte Ltd Haitong International Securities Compa ny Limited and Hait ong
International Securities (UK) Limited in reliance on ASIC Corporations (Repeal and Transitional) Instrument  2016396 which exempt s those HTISG entities from the requirement to hold an Australia n
financial services license under the Corporations Act 2001 in respect of the financial services it provides to wholesale clie nts in Australia  A copy of the ASIC Class Orders may be obtained at the
International Securities (UK) Limited are regulated under foreign laws and regulatory requirement s which are different from the laws applying in Australia
Stock Broker Merchant Banker and Research Analyst that inter alia produces and distributes research reports covering liste d entities on the BSE Limited (BSE) and the National Stock Exchang e of
India Limited (NSE) (collectively referred to as Indian Exchanges)
Name of the entity Haitong Securities India Private Limited
SEBI Research Analyst Registration Number INH000002590
Address  1203A Floor 12A Tower 2A One World Center
841 Senapati Bapat Marg Elphinstone Road Mumbai 400 013 India
Please note that Registration granted by SEBI and Certification from NISM in no way guarantee performance of the intermediar y or provide any assurance of returns to investors
This research report is intended for the recipient s only and may not be reproduced or redistribut ed without the written consen t of an authorized signatory of HTISG
Copyrig ht Haitong International Securities Group Limited 2019 All rights reserved
Source Company data Bloomberg HTI estimates